{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:12Z","timestamp":1791353772676,"version":"4.3.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,20]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>IL-3 receptor \u03b1 (CD123) expression is elevated in CML progenitor and stem cells compared with healthy donors. CD123 monoclonal antibody targeting represents a novel, potentially clinically relevant approach to deplete CML progenitor and stem cells.<\/jats:p>","DOI":"10.1182\/blood-2012-12-475194","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T05:44:54Z","timestamp":1387604694000},"page":"1218-1228","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Monoclonal antibody targeting of IL-3 receptor \u03b1 with CSL362 effectively depletes CML progenitor and stem cells"],"prefix":"10.1182","volume":"123","author":[{"given":"Eva","family":"Nievergall","sequence":"first","affiliation":[{"name":"Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"},{"name":"Center for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley S.","family":"Ramshaw","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"},{"name":"Department of Human Immunology, South Australian Pathology, Adelaide, SA, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Biondo","sequence":"additional","affiliation":[{"name":"CSL Limited, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Busfield","sequence":"additional","affiliation":[{"name":"CSL Limited, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Vairo","sequence":"additional","affiliation":[{"name":"CSL Limited, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel F.","family":"Lopez","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"},{"name":"Department of Human Immunology, South Australian Pathology, Adelaide, SA, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"},{"name":"Center for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[{"name":"Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"},{"name":"Center for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Hiwase","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2019111817351272900_B1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111817351272900_B2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia.","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111817351272900_B3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract].","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111817351272900_B4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111817351272900_B5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111817351272900_B6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111817351272900_B7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2019111817351272900_B8","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111817351272900_B9","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111817351272900_B10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111817351272900_B11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111817351272900_B12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","article-title":"Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111817351272900_B13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation.","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111817351272900_B14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111817351272900_B15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"issue":"22","key":"2019111817351272900_B16","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111817351272900_B17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111817351272900_B18","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"2","key":"2019111817351272900_B19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.leu.2403224","article-title":"Interleukin-3 receptor in acute leukemia.","volume":"18","author":"Testa","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111817351272900_B20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V89.5.1471","article-title":"The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors.","volume":"89","author":"Bagley","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2019111817351272900_B21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V82.7.1960.1960","article-title":"Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5.","volume":"82","author":"Miyajima","year":"1993","journal-title":"Blood"},{"issue":"1","key":"2019111817351272900_B22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V87.1.83.83","article-title":"Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist.","volume":"87","author":"Sun","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2019111817351272900_B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"21","key":"2019111817351272900_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3598.3598","article-title":"CSL362: a monoclonal antibody to human interleukin-3 receptor (CD123), optimized for NK cell-mediated cytotoxicity of AML stem cells [abstract].","volume":"120","author":"Busfield","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111817351272900_B25","first-page":"261","article-title":"Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia.","volume":"4","author":"Matsuo","year":"1991","journal-title":"Hum Cell"},{"issue":"3","key":"2019111817351272900_B26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.leu.2402371","article-title":"The AFT024 stromal cell line supports long-term ex vivo maintenance of engrafting multipotent human hematopoietic progenitors.","volume":"16","author":"Nolta","year":"2002","journal-title":"Leukemia"},{"issue":"11","key":"2019111817351272900_B27","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","article-title":"The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.","volume":"99","author":"Lock","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111817351272900_B28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111817351272900_B29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1359-6101(96)00047-0","article-title":"Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR\/ABL.","volume":"8","author":"Sattler","year":"1997","journal-title":"Cytokine Growth Factor Rev"},{"issue":"23","key":"2019111817351272900_B30","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"2019111817351272900_B31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38\u2014stem cells in various myeloid malignancies.","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111817351272900_B32","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia.","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111817351272900_B33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111817351272900_B34","article-title":"A neutralizing antibody (CSL362) against the interleukin-3 receptor \u03b1-chain augments the efficacy of a cytarabine\/daunorubicin induction-type therapy in preclinical xenograft models of acute myelogenous leukemia [abstract].","volume":"120","author":"Lee","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111817351272900_B35","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2019111817351272900_B36","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111817351272900_B37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"2019111817351272900_B38","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity.","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111817351272900_B39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol"},{"issue":"6","key":"2019111817351272900_B40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111817351272900_B41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111817351272900_B42","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy.","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111817351272900_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1524.1524","article-title":"Pharmacodynamic activity and preclinical safety of CSL362, a novel humanised, affinity matured monoclonal antibody against human interleukin 3 receptor [abstract].","volume":"120","author":"Herzog","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111817351272900_B44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2009.12.008","article-title":"A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR\/ABL positive acute leukemia.","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk Res"},{"issue":"12","key":"2019111817351272900_B45","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.","volume":"86","author":"Mu\u00f1oz","year":"2001","journal-title":"Haematologica"},{"issue":"3","key":"2019111817351272900_B46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111817351272900_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3625.3625","article-title":"SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML [abstract].","volume":"120","author":"Konopleva","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111817351272900_B48","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas.","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"issue":"9747","key":"2019111817351272900_B49","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/8\/1218\/1379137\/1218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/8\/1218\/1379137\/1218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:35:38Z","timestamp":1574116538000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/8\/1218\/32840\/Monoclonal-antibody-targeting-of-IL3-receptor-%CE%B1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-12-475194","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}